The short answer
Berberine can change glucose control, but added hypoglycemia with insulin isophane is not established by the reviewed studies. A monitoring plan is more justified than a predicted risk rate.
What this answer covers
Oral berberine ingredient; botanical sources, salts, doses and multi-ingredient products may differ.
- Supplement or preparation
- Berberine
- Medication ingredient
- insulin isophane
Glucose control improved in pilot studies
Small diabetes studies reported lower glucose measures with berberine. Their inspected abstracts do not establish a specific NPH regimen or an NPH-related low-glucose event rate.
A controlled experiment adds a limit
In healthy men, a single-dose clamp study increased insulin secretion when glucose was high but not under basal conditions. No side effects were reported. This challenges an assumption of indiscriminate insulin release, while leaving NPH co-use untested.
Benefit is not the same as an adverse event
Lower average glucose in uncontrolled diabetes can represent benefit. It does not itself prove dangerous hypoglycemia from the combination, nor does a short healthy-volunteer result prove safety.
Review the actual product
Discuss the exact product and amount with the diabetes team before starting or stopping it. Follow your glucose-monitoring and low-glucose treatment plan. Do not adjust insulin yourself. Keep NPH dosing and meals coordinated under the prescribed plan; no automatic supplement-related dose cut follows from these studies.
Evidence and practical considerations
Side effects & toxicity
Indirect diabetes and healthy-clamp evidence does not establish clinical hypoglycemia with exact insulin isophane; contrary basal-secretion signal retained.
- Exact scope
- Oral berberine ingredient; botanical sources, salts, doses and multi-ingredient products may differ. with Insulin isophane RxCUI1605101 IN; human NPH subcutaneous suspension label bridge.
- Medication form and route
- subcutaneous insulin isophane; oral supplement
What remains uncertain
- No exact event rate or arbitrary dose adjustment.
Factors that may matter: Product; Dose; Meals; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed human NPH insulin
Hypoglycemia can be severe. Niacin may reduce glucose lowering. Changes in glucose-active treatments and meals can require monitoring and clinician review. Intravenous and pump use prohibited.
How this applies: RxCUI1605101 IN insulin isophane; human NPH formulation bridge explicit.
Human NPH labels inform the generic insulin-isophane ingredient. Not animal insulin, rapid analogs or automatically every premix. No herb-specific event rate.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed human NPH insulin
Hypoglycemia can be severe. Niacin may reduce glucose lowering. Changes in glucose-active treatments and meals can require monitoring and clinician review. Intravenous and pump use prohibited.
How this applies: RxCUI1605101 IN insulin isophane; human NPH formulation bridge explicit.
Human NPH labels inform the generic insulin-isophane ingredient. Not animal insulin, rapid analogs or automatically every premix. No herb-specific event rate.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Newly diagnosed and poorly controlled type2diabetes cohorts.
Berberine improved glucose measures in small diabetes pilot studies; transient gastrointestinal effects were reported.
How this applies: Exact insulin isophane and oral supplement preparation boundaries retained.
Abstract does not establish an NPH-specific subgroup or hypoglycemia incidence. Full-body access failed; no regimen detail inferred.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 15healthy men in the human component; animal work not treated as clinical evidence.
Insulin secretion increased during hyperglycemia but basal secretion did not change; no side effects reported during follow-up.
How this applies: Exact insulin isophane and oral supplement preparation boundaries retained.
Healthy men, short exposure, no NPH co-use. A glucose-dependent effect does not establish safety during injected insulin treatment.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact isophane article with human NPH product bridge and source-specific clinical limits. | |
| Research summary published |
Article revision: 7bcb070517debc3f
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.